Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes

Who can take part

Inclusion Criteria: * Diagnosed with schizophrenia spectrum disorder (ICD10 codes DF20, DF21 or DF25) * Age between 18 and 60 years (both included) * Approved contraception for female participants * Treated by one of the OPUS clinics and or community psychiatry centers teams and community psychiatry in the Region of Southern Denmark or Zealand * Antipsychotic SGA treatment for at least 6 months * Stable co-medication for at least 1 month * HbA1c between 39-47 mmol/mol (both included). Two measurements with ≥3 month interval are required to confirm prediabetes. The first measurement is identified and obtained from patient journals, the second prior to enrolment * BMI ≥27 kg/m2. Two weights with ≥3 month interval are required to confirm obesity * Capable of providing informed oral and written consent Exclusion Criteria: * Diagnosis of diabetes (T1D or T2D) or a HbA1c \>47 mmol/mol * Active malignant disease within the last 5 years * Pregnancy or breast feeding * Exceeding high risk consumption limit (\>21 / 14 units of alcohol for men / women, respectively) or severe substance abuse * Unwillingness to allow home visits by a study nurse * Significant somatic disease: 1) end-stage renal failure (eGFR \<15 ml/min); 2) elevated liver function tests (liver transaminases \>2 times upper normal limit); 3) history of acute or chronic pancreatitis; 4) heart failure (NYHA class IV) or unstable angina pectoris or myocardial infarction with the last 6 months; 5) uncontrolled hypertension (systolic blood pressure \>180 mm Hg, diastolic blood pressure \>100 mm Hg) * Previous treatment with study drug or use of other weight reducing drugs within the last 6 month * Participation in other drug trials * Treatment with drugs approved for overt diabetes type 2. (Metformin not included) * Circumstances that the investigator believes will interfere with the trial

Registry changes

No changes recorded since the trial was added.